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The broad resistance to antibody-mediated neutralization of lentiviruses recently isolated from infected
hosts is a poorly understood feature which might contribute to the ability of these viruses to persist and to the
failure of experimental vaccines to protect against virulent viruses. We studied the underlying molecular mech-
anisms by examining the evolution of a neutralization-sensitive, tissue culture-adapted strain of feline immu-
nodeficiency virus upon reinoculation into specific-pathogen-free cats. Reversion to broad neutralization re-
sistance was observed in seven of seven inoculated animals and, in individual hosts, started to develop between
less than 4 and more than 15 months from infection. After comparison of the envelope sequences of the
inoculum virus, of an additional 4 neutralization-sensitive in vitro variants, and of 14 ex vivo-derived variants
(6 neutralization sensitive, 5 resistant, and 3 with intermediate phenotype), a Lys3Asn or 3Glu change at
position 481 in the V4 region of the surface glycoprotein appeared as a key player in the reversion. This
conclusion was confirmed by mutagenesis of molecularly cloned virus. Analysis of viral quasispecies and biological
clones showed that the intermediate phenotype was due to transient coexistence of neutralization-sensitive and
-resistant variants. Since the amino acid position involved was the same in four of four recent revertants, it is
suggested that the number of residues that control reversion to broad neutralization resistance in FIV might
be very limited. Amino acid 481 was found to be changed only in one of three putative long-term revertants.
These variants shared a Ser3Asn change at position 557 in region V5, which probably collaborated with other
mutations in long-term maintenance of neutralization resistance, as suggested by the study of mutagenized
virus.
Feline immunodeficiency virus (FIV) is an important patho-
gen of domestic cats and, due to extensive analogy to human
immunodeficiency virus type 1 (HIV-1), is a valuable model for
AIDS studies (16, 33, 48). Antibody-mediated neutralization of
FIV resembles that of HIV-1. Similarities include (i) a much
greater resistance to neutralizing antibodies of viruses recently
isolated from infected hosts compared to laboratory tissue
culture-adapted (TCA) strains; (ii) an unpredictable sensitivity
of primary isolates to inhibition by heterologous immune sera
(6, 14, 27); (iii) a narrow breadth of activity of neutralizing
antibodies; (iv) the presence of an important neutralization
linear determinant in the variable (V) region 3 of the surface
glycoprotein (SU) of TCA strains, whereas the neutralization
epitopes of primary isolates appear to be mainly conforma-
tional (15, 17, 31); and (v) the dependence of neutralization on
the cell substrate used (1, 39). Thus, although the functional
domains of its SU and transmembrane glycoprotein (TM) are
much less well characterized than those of HIV, FIV may help
shed light on the mechanisms and role of antibody-mediated
neutralization in lentiviral infections.
We previously reported that, following one 4-month passage
in a specific-pathogen-free (SPF) cat, a highly neutralization-
sensitive (NS) TCA strain of FIV had reverted to the broad
neutralization resistance typical of primary isolates and that
the SU of the revertant differed from the parental virus at two
amino acid positions (469 and 481) within the V4 region (7).
However, it remained to be determined whether reversion to
the neutralization-resistant (NR) phenotype typical of wild-
type virus (heretofore indicated as NS3NR reversion) was a
general consequence of readaptation in vivo and, if so, whether
it was associated with constant or diverse amino acid changes.
Here, we show that such reversion is a general occurrence al-
though, in individual cats, it may take variably long to develop.
Moreover, analysis of numerous in vitro and ex vivo NS and
NR variants as well as of biological and molecular clones has
identified amino acid position 481 of SU as a major player in
the reversion.
MATERIALS AND METHODS
Progenitor and variant viruses. The progenitor TCA virus was the Petaluma
strain of FIV produced by chronically infected FL4 cells (49; generous gift of
Janet K. Yamamoto). In our laboratory, FL4 cells are routinely split 1:5 twice
weekly. Viral stocks were obtained by harvesting supernatants at cell passages
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181 (stock FL-181), 193 (FL-193), and 381 (FL-381). Female SPF cats (Iffa
Credo, L’Arbresle, France) were infected intravenously with 1 ml of viral stock
FL-193, corresponding to approximately 20 50% cat infectious doses, when 7 to
12 months old. Virus reisolations were performed by standard coculture of
peripheral blood mononuclear cells with MBM cells. This line of feline CD31,
CD42, and CD82 T lymphocytes is routinely cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 5 mg of concanavalin A, and 20 U of
recombinant human interleukin-2 per ml. Reisolations varied only slightly in the
time that they were first positive and the levels of reverse transcriptase produced,
and three to five amplifications in MBM cells were sufficient to accumulate viral
stocks of suitable titer. MBM cells were also used to produce some in vitro
variants so that, with three exceptions in which supernatant of FL4 cultures was
used, the virus stocks used in neutralization assays consisted of MBM cell fluids.
The fluids were clarified at 350 g for 15 min, were stored in 1-ml aliquots in liquid
nitrogen, and were subjected to titer determination at least twice in quadrupli-
cate by endpoint dilution in a microtiter MBM cell assay after 1 h at 4°C, i.e., with
the same incubation conditions used for the neutralization test. No differences
were noted in replication kinetics between the progenitor and variant viruses.
Titers ranged between 2 3 102 and 1 3 103 50% tissue culture infective doses
(TCID50) per ml.
Neutralization assay. Virus neutralization was performed as previously de-
scribed (14) against 10 TCID50 of FIV and MBM cells grown in the presence of
6% pooled normal cat serum as indicator cells. Immune sera were generally
diluted 1:8, 1:32, 1:128, and 1:512 (dilutions before the addition of virus and
cells), and each experiment included controls receiving virus incubated with
identical dilutions of normal cat serum. Neutralizing antibody titers were defined
as the reciprocal of the serum dilution required to reduce by $50% the levels of
reverse transcriptase activity produced in the presence of the corresponding
dilution of normal cat serum and were calculated according to Reed and Mu¨ench
(35). All experiments were repeated at least twice. In general, reproducibility was
satisfactory since titers with a given virus-serum combination exhibited a maxi-
mum twofold deviation between experiments, which is within the expected error
of neutralization assays with the format used.
Criteria for scoring the neutralization phenotype of virus variants. The neu-
tralization sensitivity of viral variants was probed against a panel of 11 heat-
inactivated sera taken from eight FIV-infected cats at varying times postinfection
(p.i.; see legend to Table 1). Based on the neutralization properties of primary
FIV isolates (14), variants were considered NS when they were neutralized by at
least nine test sera with an average titer of $128, NR if neutralized by no more
than four sera with a mean titer of #32, and intermediate (NI) when they
exhibited in-between sensitivity.
DNA isolation, sequencing, and genetic analyses. DNA was extracted from
6 3 106 infected cells with phenol-chloroform and was checked for integrity by
ethidium bromide-stained 0.8% agarose gel and for amplificability by using feline
tumor necrosis factor alpha primers. PCR amplification of env was performed as
described previously (34). For SU sequencing, DNA was amplified by nested
PCR, using flanking primers 237HS (59-AGTAAACCCATTTAGGGTACCTG-
39; positions 6377 to 6399), 238AS (59-CTCATCCCAGTCCACCCTTTTTTC-
39; positions 9103 to 9126), and 16AS (59-CAGAAGAATTGATTTTGATTAC
A-39; positions 8358 to 8380). Primers 237HS and 238AS were used for the first
step and primers 237HS and 16AS for the second. The TM region was amplified
by single-step PCR by using the primers V4S (59-AACCTTTGCAATGAGAA
GTT-39; positions 7532 to 7551) and 238AS. Amplicons were then subjected to
cycle sequencing using internal fluorescent-labeled primers overlapping the en-
tire env. Nucleotide (nt) sequences were edited and translated by PC/Gene
software (IntelliGenetics, Geel, Belgium). Selected regions were resequenced to
confirm the substitutions that distinguished the variants. Predicted amino acid
sequences were obtained with the TRANSL program, and glycosylation sites
were determined with PROSITE of the PC/Gene package.
DNA sequences obtained from this and a previous study (7) were aligned by
using the program CLUSTAL W (46). Genetic distance matrices were generated
by using the DNADIST program of the PHYLIP software package, version 3.5c
(University of Washington, Seattle), using Kimura’s two-parameter method (20)
to correct for superimposed substitutions and a transition/transversion of 2.0.
Divergence per year was calculated as follows: distance between parental and
isolate sequences at 15 months divided by 15 and multiplied by 12.
Quasispecies analysis. Viral RNA from virus stocks was reverse transcribed
and amplified with first-step primers pV3S (59-TGTTATGTAGACAGAGTAG
AT-39; positions 7113 to 7133) and pV4AS (59-TGCAAGACCAATTTCCAGC
A-39; positions 7847 to 7866), and the product of this reaction was reamplified for
25 cycles with internal primers pV4S2 (59-TAGATGTAGATGGAATGTAG-39;
positions 7643 to 7662) and pV4AS2 (59-CACAATAAGGTCATCTACCT-39;
positions 7789 to 7808). The 166-bp fragments of region V4 thus obtained were
then subjected to single-strand conformation polymorphism (SSCP) analysis as
reported previously (14) except that electrophoresis was carried out in 15%
nondenaturing polyacrylamide gel. Following silver staining and washing of the
gels in distilled water for at least 1 h, the SSCP bands were excised, directly
amplified, and sequenced.
Biological clones. Biological clones were obtained using a modification of a
method previously described for HIV-1 (28). Briefly, 10 TCID50 of virus were
incubated with 5 3 106 MBM cells at 37°C in 5% CO2 for 4 h. After thorough
washing to remove any unabsorbed virus, numbers of cells ranging from 100 to
105 were seeded into microwells containing 105 MBM cells in 100 ml of complete
medium (16 wells/dilution), in order to expand the virus produced by single
infected cells. The supernatants were monitored for p25 twice weekly for 1
month, and the ones found positive that had been seeded with the lowest
numbers of virus-exposed cells were examined for quasispecies composition as
described above. The cultures that produced a single SSCP band were used as a
source of biologically cloned virus. The clones were expanded, filtered, frozen in
small aliquots in liquid nitrogen, subjected to titer determination, sequenced to
confirm the genotype inferred from SSCP analysis, and examined for neutral-
ization phenotype.
Molecular clones. The entire env of the NS virus cultured from cat 275 at 1
month p.i. was amplified using primers ORFA1s (59-GGTCGGGAGAACTAT
GAATGG-39; positions 5974 to 5994) and LPCRas (59-GCTGTCTCCCGTTG
TAGAAGTCG-39; positions 9046 to 9069) with proofreading Expand High
Fidelity DNA polymerase (Hoffman-La Roche, Basel, Switzerland) and was
cloned into the Topo TA cloning vector (Invitrogen, Carlsbad, Calif.). Site-
specific mutagenesis was carried out on this construct by inverse PCR, using 59
phosphorylated primers, the above polymerase, and a low number of cycles.
Amplicons were ligated with T4 DNA polymerase (New England Biolabs, Bev-
erly, Mass.) and were introduced into JM109 bacteria. Unaltered and mu-
tagenized env fragments were then inserted into p34TF10 (44), which had been
rendered able to grow in lymphocytes by removing the stop codon at position
6210 of open reading frame A. Virus stocks were produced by transfecting into
CrFK cells and expanding in MBM cells. Proper insertion and the absence of
unwanted mutations were checked by sequencing the entire env at each step.
RESULTS
NS3NR reversion. In a previous study, growth in vivo for 4
months had caused FIV stock FL-181 to revert to the broad
neutralization resistance typical of primary isolates (7). To
assess whether this was a constant outcome of propagating
TCA FIV in vivo, we tested for neutralization, by a panel of
immune sera, three viruses (338:36, 2906:36, and 3368:36) rei-
solated from cats 3 years after infection with the same stock.
All proved to be NR as primary FIV isolates (data not shown).
In contrast, additional propagation of the producer FL4 cells
for up to 24 months (variants FL-193 and FL-381) or mere
passaging in MBM cells (variant 193/MBM in this study and
variant 181/MBM of reference 7) had no effects on the neu-
tralization sensitivity of TCA FIV.
To further characterize the reversion, we studied consecu-
tive virus samples from three SPF cats (no. 275, 311, and 583)
inoculated with stock FL-193. The animals had become readily
infected (Fig. 1); however, virus was cultured at all times tested
only from two cats. Cat 311 was uniformly provirus positive and
showed a prompt anti-FIV antibody response (Fig. 1B) but
yielded the first positive culture at 10 months p.i. Failure to
retrieve the virus from this cat at earlier time points was not
unprecedented (2, 23) and was attributed to reduced virulence
of TCA FIV for cats, as shown by relatively low provirus loads,
low or negative postacute plasma viremias, and the absence of
significant T-cell subset count changes (Fig. 1A and data not
shown). Table 1 shows the neutralization behavior of reiso-
lated viruses. The virus from cat 275 was as NS as the inoculum
virus at 1 and 3 months, possessed an NI phenotype at 6
months, and scored NR at 10 and 15 months. The 10- and
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15-month isolates from cat 311 both scored NR. In cat 583, the
virus remained fully NS for at least 10 months, at 15 months
was NI, and at 20 months still scored as NI although it had
clearly progressed further toward global resistance. Thus,
NS3NR reversion was a constant consequence of TCA FIV
readaptation in vivo although it occurred after variably long
time intervals in individual cats. The results also showed that
the reversion could develop in a graded manner but affected in
parallel the neutralizing efficiency of all panel sera, indicating
that what was being observed was indeed the reacquisition of a
neutralization phenotype typical of primary FIV isolates.
Timing of NS3NR reversion relative to development of
resistance to autologous antibodies. The consecutive viral sam-
ples described above were also tested in checkerboard assays
for neutralization by consecutive sera derived from the same
animals. Early isolates were effectively inhibited by all sera
harvested 3 or more months p.i. but resisted neutralization by
autologous sera collected at any time prior to virus reisolation.
In contrast, late isolates resisted most sera and were inhibited
exclusively, and very inefficiently, by some contemporary and
subsequent autologous sera (Table 2). Thus, these findings
showed that the NS3NR reversion developed considerably
later than resistance to autologous antibodies. The analysis
also showed that individual cats had developed at least partly
distinct repertoires of neutralizing antibodies, as revealed by
the partially different patterns of viral isolates neutralized (Ta-
ble 2), and that this had occurred in concomitance with the
marked decrease in circulating viral loads observed between
month 1 and 3 p.i. (Fig. 1A), thus suggesting that neutralizing
antibodies had participated in curbing the acute phase of viral
replication.
SU gene changes over time. The SU genes (nt positions 6798
to 8097) of the above consecutive isolates and of three in vitro
variants (FL-193, 193/MBM, and FL-381) were amplified from
DNA of the cells used for viral stock production and were
bidirectionally sequenced in their entirety. None of the nt
sequences obtained had premature stop codons, deletions, or
insertions, but all differed from each other and from parental
virus, indicating that they were independent.
As shown in Table 3, the 15-month isolates from cats 275
and 311 diverged from parental virus by 0.85 and 0.70%, re-
spectively, with an average divergence rate of 0.62% per year.
FIG. 1. Follow-up of FIV infection in three cats infected with TCA
FIV. (A) Numbers of proviruses in the peripheral blood mononuclear
cells measured by competitive PCR as described previously (25). (B)
Antibody titers to whole FIV antigen measured by enzyme-linked
immunosorbent assay (25). E, cat 275; h, cat 311; , cat 583.
TABLE 1. Neutralizability of consecutive isolates obtained from cats infected with TCA FIV, as determined with a panel of immune sera
Immune
seruma
Neutralizing antibody titer with virus isolate obtained from:b
Cat 275 at indicated mo p.i.
Cat 311 at
indicated
mo p.i.
Cat 583 at indicated mo p.i.
1 3 6 10 15 10 15 1 3 6 10 15 20
2581-9 128 512 11 2 2 8 2 128 181 181 .512 45 2
857-12 32 181 11 2 2 2 2 8 2 8 NDc 45 11
874-12 512 512 152 32 2 45 8 .512 .512 .512 .512 45 8
902-12 128 512 11 2 2 2 2 .512 .512 128 512 181 2
905-12 128 512 11 2 2 2 2 2 8 64 194 11 2
338-32 181 128 8 2 2 38 2 .512 512 .512 .512 14 32
2906-32 512 181 13 2 2 2 2 .512 512 .512 181 11 2
3368-32 128 181 11 2 2 11 2 512 .512 512 181 45 45
338-41 181 .512 11 2 2 2 2 .512 .512 .512 512 181 157
2906-41 512 45 11 2 2 2 2 512 .512 .512 128 11 ND
3368-41 .512 181 11 2 2 2 2 .512 512 .512 128 38 11
a The number before the dash identifies the donor cat; the number after the dash identifies the month p.i. when the serum was obtained. Cats were infected with
virus FL-181 (no. 338, 2906, and 3368) or with the same virus passaged three (no. 2581) or six (no. 857, 874, 902, and 905) times in SPF cats.
b Values shown are the geometric means of the titers obtained in two independent assays. 2, no neutralizing activity detected; mean titers of ,8 were not considered
significant and were scored as negative.
c ND, not done.
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This rate was higher than the 0.41% previously found in a
long-term naturally infected cat (21) and was slightly less than
that calculated for HIV-1 and simian immunodeficiency virus
(5, 51). The 15-month isolate from cat 583 diverged from the
inoculum by only 0.15%, and this was attributable to an espe-
cially high frequency of back mutations, as revealed by inter-
isolate divergence rates essentially equivalent to that observed
in the other cats. The latter rates were especially high during
the first month, most likely as a result of exuberant virus
replication in the acute phase (Fig. 1) and of the virus’s need
to readapt to the intrahost environment, and subsequently
declined, first rapidly and later more gradually. These findings
were consistent with data showing that selective pressure for
change in HIV-1 is host dependent (51) and suggested that in
cat 583 the selective forces driving virus evolution were weaker
than in the other two animals, which might explain why in this
animal NS3NR reversion had occurred later than in the oth-
ers. It is unfortunate that the ratio of mutated synonymous and
nonsynonymous codon sites, which might have corroborated
this conclusion, was not informative due to low total numbers
of mutations. It is also noteworthy that in cats 275 and 583, for
which the time of reversion was precisely known, this occurred
during a phase of relatively slow evolution, indicating that it
had required limited mutational changes.
Figure 2 shows the SU amino acid alignment for all the
variants described above and for three similar variants (FL-
181, 181/MBM, and 3524:4mo) studied previously and de-
scribed in an earlier report (7). The SU of FIV contains vari-
able regions interspersed between more conserved segments
(29). Amino acid substitutions were not randomly distributed
since variation was especially high in the V3 and V4 regions.
Interestingly, for V3 this was true regardless of the in vitro or
ex vivo source (Fig. 3), suggesting that at least part of its
variation might be independent of the in vivo environment, as
observed for the corresponding region of HIV-1 (50). Further-
more, the V3 of the NR and NS variants contained similar
numbers of amino acid changes, in accord with the idea that it
may possibly serve as a decoy to distract the immune system
from more critical regions (6, 27, 31) but is of less or no
importance for determining global neutralization resistance. In
contrast, the V4 of the NR and NI variants accumulated more
changes than the NS counterparts, hence clearly suggesting its
implication in NS3NR reversion.
Table 4 summarizes the differential amino acid changes de-
tected in the NR and NI variants and not found in any of the
NS variants. Clearly, position 481 emerged as a critical residue
since (i) it was substituted in each of the NR variants; (ii) it was
replaced also in the three NI variants although in one (variant
583:15mo) the replacement was incomplete; (iii) timing of the
replacement correlated with the onset of NS3NR reversion
(Table 1); (iv) in one NR and two NI variants, it was the only
position substituted, thus demonstrating that changes at this
site were sufficient to confer the NR phenotype; and (v) the
other positions were substituted in a maximum of two variants
derived from a single cat, suggesting that they may have con-
tributed to resistance to autologous antibodies or other im-
TABLE 2. Neutralizability of consecutive virus samples obtained from cats infected with TCA FIV by consecutive sera from the same cats
Serum
Neutralizing antibody titer with virus isolate obtained from:a
Cat 275 at indicated mo p.i.
Cat 311 at
indicated
mo p.i.
Cat 583 at indicated mo p.i.
Donor
cat
Mo p.i. at
collection 1 3 6 10 15 10 15 1 3 6 10 15 20
275 1 2 2 2 2 2 2 2 2 8 2 2 2 2
3 181 2 2 2 2 2 2 181 512 512 45 32 2
6 .512 45 2 2 2 2 2 .512 .512 .512 181 11 2
10 .512 76 8 2 2 2 2 .512 .512 .512 .512 2 2
15 .512 512 32 8 2 2 2 .512 .512 .512 .512 181 2
311 1 2 2 2 2 2 2 2 2 2 11 11 2 2
3 .512 11 11 2 2 2 2 .512 .512 .512 .512 2 2
6 .512 .512 8 2 2 2 2 .512 .512 .512 .512 2 2
10 .512 181 45 2 2 11 11 .512 .512 .512 .512 11 2
15 .512 512 57 2 2 20 2 .512 .512 .512 .512 11 2
583 1 8 2 2 2 2 2 2 128 38 11 2 2 2
3 .512 11 2 2 2 2 2 512 181 181 64 11 2
6 512 2 2 2 2 2 2 181 .128 181 181 2 2
10 .512 8 2 2 2 2 2 512 .128 181 181 11 2
15 .512 2 2 2 2 2 2 512 .128 181 181 2 2
a Values shown are the geometric means of the titers obtained in two independent assays. 2, no neutralizing activity detected; mean titers of ,8 were not considered
significant and were scored as negative.
TABLE 3. Genome divergence analysis of sequential isolates
obtained from cats infected with TCA FIVa
Cat
% Divergence
from parental
virus at
15 mo p.i.
% Divergence from parental virus
or previous isolate per mo
Total Per year 0–1 1–3 3–6 6–10 10–15 15–20
275 0.85 0.68 0.54 0.23 0.10 0.06 0.14 NDb
311 0.70 0.56 ™™™™™™™™™™™™™™™3 0.21c 0.03 ND
583 0.15 0.12 0.46 0.31 0.18 0.16 0.09 0.03
a Kimura’s two-parameter distances as calculated from pairwise comparison of
the available sequential isolates.
b ND, not done; at 20 months, only the virus culture from cat 583 was per-
formed.
c % Divergence between parental virus and isolate at 10 mo.
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mune effectors (18, 26) but played little if any role in NS3NR
reversion. Regarding the residues present at position 481 of
the NR variants, the Lys of the parental virus was substituted
for by either Asn or Glu. In the former case, the revertants had
acquired one additional potential N-linked glycosylation site in
V4. Another additional predicted glycosylation site was pres-
ent at position 469 in some ex vivo variants but did not corre-
late with neutralization resistance (Fig. 2).
V4 quasispecies during NS3NR reversion. The readout of
the neutralization assay used was expected to be determined by
the most prominent variant in the virus stock. It was, therefore,
of interest to investigate whether gradual acquisition of the NR
phenotype was due to the gradual accumulation of mutations
or to the time needed for the Asn-481 and Glu-481 sequences
to become sufficiently abundant. We hence compared inocu-
lum virus and the consecutive ex vivo isolates for quasispecies
composition in a 166-bp segment of the V4 region encompass-
ing position 481 (Fig. 4). The inoculum was found to be com-
posed of three distinct sequences in the region examined, all
with a Lys at position 481. The acute phase of replication in
vivo was characterized by a simplification of quasispecies com-
plexity, similar to that observed in seroconverting HIV-1 indi-
viduals (52, 53). Subsequently, the number of distinct se-
quences fluctuated between 1 and 3. It is of particular interest,
however, that Asn-481 and Glu-481 sequences first became
evident at different time points in individual hosts, initially
coexisted with Lys-481 sequences for variable times, but even-
tually became the predominant (cat 583) sequence or the only
one demonstrable. Since this gradual takeover paralleled the
kinetics of NS3NR reversion (Tables 1 and 2), we concluded
that the coexistence of parental and Asn-481 or Glu-481 se-
quences in the viral population was the most likely explanation
for the NI phenotype.
Neutralization phenotype of biological clones. Biological
clones were derived from the NI virus cultured from cat 583 at
15 months p.i. and were studied by SSCP in the V4 region.
Each clone gave a single band in a position that, in the original
uncloned virus, was typical either of Lys-481 or Asn-481 se-
quences (data not shown). Four clones selected randomly from
each of these two groups were assayed for their neutralization
phenotype, and their SU was sequenced. All clones that had
given a Lys-481 band proved NS while all clones with an Asn-
481 band were NR (Table 5). Invariably, sequence analysis of
these eight clones confirmed the genotype inferred from SSCP
analysis. A similar study with the NR virus cultured from cat
275 at 10 months p.i. led to Glu-481 clones only, as determined
by SSCP and sequence analysis, indicating a high prevalence of
this genome, and each clone proved NR (results not shown).
Thus, these findings corroborated the conclusions of quasispe-
cies analysis.
SU sequences of putative long-term revertants. We also
sequenced the SU of the NR variants 338:36, 2906:36, and
3368:36 (sequences available by e-mail on request), which had
been obtained from animals infected with the FL-181 stock 3
years previously (see above) and were likely to have reverted to
broad neutralization resistance long before sampling. Lys-481
was found replaced (by Glu) only in one of these putative
long-term revertants. However, all had Ser-557 replaced by an
Asn, resulting in an additional potential glycosylation site in
V5. Although this suggested that such change was important
for neutralization resistance, each of these variants displayed a
minimum of two differential amino acids (Table 4), rendering
identification of key changes problematic.
TM sequences. In HIV-1, changes within TM have been
seen to impact SU conformation and regulate susceptibility to
selected neutralizing antibodies (6, 27, 31, 45). In FIV, TM
changes have been seen to affect cell tropism (47), and immu-
nization with a TM peptide conferred some protection against
subsequent virus challenge (38). For investigating whether TM
mutations could have contributed to the reduction of virus
neutralizability, we sequenced the encoding gene of one NI
and five NR variants (sequences available by e-mail on re-
quest). One NR and one NI variant showed no amino acid
changes compared to the NS variant used as a reference. The
others showed one to three substitutions irregularly dispersed
through the extracellular, transmembrane, or intracellular do-
mains. In particular, there was no single position which was
FIG. 3. Distribution of predicted amino acid changes relative to
progenitor TCA FIV in the V3, V4, and V5 regions and in the rest of
the SU of the viral variants listed in Fig. 2, grouped by source and
neutralization phenotype. The figures under the bars represent the
mean number of changes per amino acid position in the indicated SU
regions 6 the standard error for the groups of variants depicted above,
while overall variation is the same parameter for all the variants.
Variable regions V3 to V5 are delineated as shown in Fig. 2. Bars
represent individual variants.
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affected in all the NR variants. These findings ruled out the
possibility that the TM protein played a major role in NS3NR
reversion.
Neutralization phenotype of molecularly cloned viruses. The
above data had strongly suggested that amino acid positions
481 and 557 were important in reacquisition and, possibly,
maintenance of the NR phenotype by TCA FIV. To confirm
the importance of these positions, we generated mutagenized
molecular clones as described in Materials and Methods.
When transfected into CrFK cells and expanded in MBM cells,
all clones led to the production of viral stocks suitable for the
neutralization assays except the ones with Glu-481, which—for
reasons that have remained unclear—either gave a single cycle
of replication (three clones) or rapidly reverted to Lys-481
(one clone). As shown in Table 6, Asn-481 conferred complete
resistance to all the four sera tested and Asn-557 did to only
two sera, thus suggesting that while the former change was
sufficient for broad neutralization resistance, the latter proba-
bly required the coexistence of additional mutations.
DISCUSSION
We have approached the issue of the poor sensitivity to
antibody-mediated neutralization of wild-type lentiviruses by
investigating the evolution of an NS TCA strain of FIV upon
reinoculation into its natural host. The reversion to the NR
phenotype typical of primary isolates was a uniform outcome
of readaptation in vivo, thus indicating that this phenotype is
an important survival factor in vivo for FIV as well as for other
lentiviruses (4, 5, 10, 19). That the reversion took variable
numbers of months to develop suggests that broad neutraliza-
tion resistance is necessary, especially for long-term viral per-
sistence. This, together with the fact that all the virus variants
studied grew equally well in culture regardless of neutraliza-
tion phenotype, also makes it unlikely that substrate-controlled
epigenetic changes or improved tropism for specific target cells
were important causes of NS3NR reversion (2, 3, 8, 30, 40,
43). It is therefore plausible that reversion was driven by the
host’s immune response. Accordingly, the transition was slow-
est in cat 583, which also exhibited the weakest anti-FIV en-
zyme-linked immunosorbent assay antibody response and the
lowest rate of SU change. The present findings also indicate
that TCA viruses should not be used as the challenge in vaccine
experiments even if repassaged in vivo for some time, unless
their complete reversal to wild-type phenotype has been veri-
fied.
Env analysis of consecutive virus samples obtained from cats
infected with the TCA FIV under study identified amino acid
position 481, located centrally in the V4 region, as a key de-
terminant of NS3NR reversion since (i) substitution of either
Asn or Glu for Lys-481 was common to each of the virus
samples with an NI or NR phenotype but was not found in any
of the NS variants; (ii) emergence and takeover of the se-
quences containing these substitutions coincided temporally
with the development of the NR phenotype; and (iii) in one
NR and two NI variants, amino acid 481 was the only differ-
ential position compared to NS variants, thus suggesting that
this change alone was sufficient for acquisition of the NR
phenotype. The importance of amino acid 481 was confirmed
by the phenotype of biological and molecular clones. All clones
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with Asn-481 or Glu-481 effectively resisted neutralization,
whereas the ones with Lys-481 were as NS as the TCA virus.
The additional, sporadic differential amino acids observed in
some consecutive virus samples were dispersed throughout
Env and were temporally unrelated to the transition. Thus,
they may have represented escape mutations that protected
the virus from the in vivo ongoing action of specific subsets of
neutralizing antibodies and other immune effectors (18, 26, 31)
but appeared unimportant for global neutralization resistance.
Studies with lentiviruses and other viruses have shown that
single amino acid substitutions, within critical linear or discon-
tinuous epitopes or even located at a distance, can permit
escape from specific immune sera or sets of monoclonal neu-
tralizing antibodies. For example, substituting a Leu or Thr for
Ser-483 was shown to render a molecular clone of the Amster-
dam 19 strain of FIV susceptible to neutralization by an oth-
erwise ineffective antiserum raised against a different clone of
the same strain (41). In HIV-1, there is also evidence that
certain amino acid positions within Env control neutralizability
on a large scale (6, 27, 32). The present findings represent the
first indication that a single amino acid change can bring about
a general resistance of FIV to neutralization. Since the diverse
polyclonal sera we used to probe neutralizability are expected
to have simultaneously acted upon multiple epitopes and clus-
ters of epitopes and most if not all the neutralization epitopes
of wild-type FIV operative in the lymphoid cell-based assay
used here are conformation-dependent (17, 37), they also rep-
resent evidence that distinct conformation-determining amino
acids exist within SU which prevent the functionality of mul-
tiple FIV neutralization epitopes. The replacements of amino
acid 481 associated with broad neutralization resistance re-
sulted either in the introduction of a potential glycosylation
site (Lys3Asn) or in a change of charge polarity (Lys3Glu),
events that may have influenced tertiary and quaternary struc-
ture, such as a condensation of SU or altered intramolecular
interactions within Env oligomeric spikes (10, 12, 36).
It has been calculated that lentivirus-infected hosts are con-
fronted with every possible virus mutation on a daily basis (11).
That changes at amino acid 481 were associated with NS3NR
reversion in 4 of 4 hosts is, therefore, of considerable interest.
Because host cats were not siblings and their sera displayed
partially different patterns of neutralizing activity in checker-
board tests, it seems unlikely that this was due to a stereotyped
immune response. It is, instead, more likely that changes at this
position provided such a selective advantage in vivo as to
represent a highly preferable pathway for virus evolution. Sim-
ilar to what was suggested by recent findings with TCA chi-
meric simian HIV (9), this in turn may imply that the number
of Env residues responsible for broad neutralization resistance
of fresh isolates is very limited. It is notable that virtually all the
FIG. 4. Quasispecies composition in the V4 region of consecutive isolates obtained from cats infected with TCA FIV as determined by SSCP
analysis and sequencing of the resulting bands. Sequences derived from individual bands differed in 1 to 6 nt. The ones with Lys-481 replaced are
marked E for Glu or N for Asn.
TABLE 5. Neutralizability of biological clones derived from
the NI virus cultured from cat 583 at month 15 p.i.
Immune
seruma
Neutralizing antibody titerb
Clone with Lys-481 Clone with Asn-481
B7 C1 G5 H1 B1 C6 C9 H8
902-12 181 45 32 45 2 8 2 2
905-12 11 8 8 2 2 2 2 2
338-41 512 45 32 128 2 2 2 2
2906-41 45 11 10 128 2 2 2 2
a The number before the dash identifies the donor cat; the number after the
dash identifies the month p.i. when the serum was obtained.
b Values shown are the geometric means of the titers obtained in two inde-
pendent assays. 2, no neutralizing activity detected; mean titers of ,8 were not
considered significant and were scored as negative.
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SU sequenced from field FIV isolates possess an Asn-481
irrespective of the clade in which they are classified (34).
Finally, it is of interest that Lys-481 was found to be replaced
(by an Asn) in only 1 of 3 NR variants first reisolated from cats
inoculated with TCA FIV 3 years earlier. In such putative
long-term revertants, precise definition of the position(s) re-
sponsible for resistance was problematic due to the presence of
at least two differential SU residues relative to NS variants.
Although these revertants shared a Ser3Asn mutation at po-
sition 557 in the V5 region, a molecular clone with Asn-557
proved still partially neutralizable. It is, therefore, likely that
changes at this position determine the broadly resistant phe-
notype only when associated with other substitutions. Because
no earlier samples of these variants were available, we cannot
discriminate whether they developed upon viruses that already
had become NR due to 481 changes, which would have dem-
onstrated that the genetic bases of the NR phenotype evolve
with the duration of infection, or instead stemmed directly
from NS virus, which would have shown that alternative routes
to NS3NR reversion exist. A Lys3Gln change at position 560
of V5 was previously seen to render a molecular clone of the
Amsterdam 19 strain of FIV resistant to neutralization by an
autologous antiserum (42). It is also noteworthy that neither
position 557 nor position 481 has been implicated as a deter-
minant of FIV tropism to different cell types (13, 22).
In conclusion, if extended to other TCA strains, the ap-
proach used here may permit identification of Env determi-
nants that confer broad neutralization resistance to wild-type
FIV, eventually providing leads for the development of vac-
cines effective against difficult-to-neutralize strains.
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